Skip to content

Exercise in Testicular Germ Cell Cancer Survivors

Exercise in Prevention & Treatment of Chemotherapy-related Late Toxicity in Testicular Germ Cell Cancer Survivors: the Role of Skeletal Muscle

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05063760
Acronym
ExCell
Enrollment
60
Registered
2021-10-01
Start date
2020-01-15
Completion date
2024-06-30
Last updated
2023-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Testicular Germ Cell Tumor

Keywords

TGCT, exercise intervention, Magnetic resonance spectroscopy, skeletal muscle, chemotherapy-induced metabolic toxicity

Brief summary

Regular exercise is effective in prevention & treatment of chronic diseases. Exercise can reduce late toxicity of chemotherapy, commonly found in cancer survivors, which is yet to be translated into clinical practice. Mechanisms of exercise benefits in oncologic patients are far from being elucidated, and include increase in muscle mass, reduction of fat mass, systemic inflammation and cardiometabolic risk. Synchronization of exercise adaptive response is, to an extent, mediated by bioactive molecules released from muscle, with anti-inflammatory & tumor-suppressing properties. Muscle satellite cells are a source of regeneration, muscle structural integrity & functional capacity. Phenotypes of muscle cells, such as secretory profile, lipid & glucose metabolism, mirror clinical phenotypes of the donor. Importantly, muscle cells' metabolism in vitro can be modulated by 8-12 week training in vivo. Epigenetic mechanisms regulating muscle & systemic metabolism in cancer survivors are not yet understood.

Detailed description

Aims: * To assess the impact of 6-month supervised, individualized aerobic-strength exercise training intervention in cancer survivors with chemotherapy-induced late toxicity . (i) on the whole-body energy and glucose metabolism, anthropometric parameters, physical fitness & activity profile, motor functions and quality of life in testicular germ cell cancer (TGCC) survivors, more than 3 years after cisplatin-based chemotherapy; with the 2-year follow up; . (ii) on skeletal muscle mass, morphology as well as functional and metabolic state detected in vivo (31P-MR spectroscopy). (iii) on metabolic characteristics of primary skeletal muscle cells; * To determine the impact of exercise intervention on circulating bioactive molecules (exerkines), putative mediators of exercise health benefits as well as on levels of circulating inflammatory cytokines, which likely contribute to the pathogenesis of chemotherapy-induced late toxicity; * To evaluate the role of (a) selected exercise-regulated bioactive molecules, (b) exercise-mimicking treatment (by electric pulse stimulation) and (c) cisplatin treatment on metabolism and mitochondrial function of differentiated human muscle cells in culture; * To investigate the associations between intervention-induced shifts in circulating bioactive molecules and selected metabolic, anthropometric and motor parameters. The generated results will enable us (i) to gain a better insight into pathomechanisms of muscle-associated chemotherapy-induced late toxicity and the role of skeletal muscle & systemic mediators in the exercise-induced health benefits in TGCC survivors; and (ii) to validate the effectiveness of the individually-tailored exercise intervention in reducing chemotherapy-related toxicity in patients with TGCC, with the aim to transfer this knowledge into clinical practice.

Interventions

BEHAVIORALaerobic-strength exercise intervention (6-months)

6 month supervised exercise intervention in TGCT survivors (1 hour sessions 3 x per week),

Sponsors

Comenius University
CollaboratorOTHER
Slovak Academy of Sciences
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

lab technicians and statistician are blinded.

Intervention model description

controled trial with exercise intervention

Eligibility

Sex/Gender
MALE
Age
25 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* TGCT survivors, with chemotherapy-induced metabolic toxicity, men, 25-55 years old, with the capacity to undergo training, signed written informed consent

Exclusion criteria

* serious / uncontrolled chronic diseases, non-compliance, other health issues as assessed by oncologists / investigators

Design outcomes

Primary

MeasureTime frameDescription
change in the glucose toleranceparameter will be measured before and after 6 month interventionchange in glucose tolerance (as measured by oral glucose tolerance test)
change in resting energy expenditiure and metabolic substrate preferenceparameters will be measured twice before and after 6 month interventionchange in resting energy expenditure calculated by Weir equation from VO2 and metabolic substrate preference RQ VCO2/VO2 (as measured by indirect calorimetry)
change anthropometric parameters of obesityparameters will be measured twice before and after 6 month interventionBMI (kg.m-2) , fat mass (% electric bioimpedance), lean body mass (% electric bioimpedance), visceral adiposity (%, elecgtric bioimpedance)
change physical fitnessparameter will be measured twice before and after 6 month interventionVO2max (mlO2 per kg BW min) as measured by bicycle spiroergometry

Secondary

MeasureTime frameDescription
change in muscle strengthmeasured twice before and after 6 month interventiondynamometry
change in cognitive functionsmeasured twice before and after 6 month interventionstandardised cognitive test Cogstate
change in quality of life for cancer patientsmeasured twice before and after 6 month interventionvalidated questionnaire

Countries

Slovakia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026